Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide

A phase 2, randomized, active-controlled study of initial antiretroviral therapy with bictegravir or dolutegravir in combination with emtricitabine and tenofovir alafenamide showed excellent efficacy. After 60 weeks of blinded treatment, participants switched to a single-tablet regimen of bictegravi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sax, Paul E., DeJesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Dretler, Robin, Mills, Anthony, Brinson, Cynthia, Wei, Xuelian, Collins, Sean E., Cheng, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082593/
https://www.ncbi.nlm.nih.gov/pubmed/29794828
http://dx.doi.org/10.1097/QAD.0000000000001894
Descripción
Sumario:A phase 2, randomized, active-controlled study of initial antiretroviral therapy with bictegravir or dolutegravir in combination with emtricitabine and tenofovir alafenamide showed excellent efficacy. After 60 weeks of blinded treatment, participants switched to a single-tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide. Switching maintained viral suppression in all participants who remained on the study through 12 weeks in the open-label phase, and was safe and well tolerated.

Ejemplares similares